A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH) (IMPAHCT)
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients With Pulmonary Arterial Hypertension (PAH)
Sponsor: Aerovate Therapeutics
Terminated
The IMPAHCT study demonstrated that while inhaled imatinib was well tolerated, it did not prove to be efficacious at any of the doses of AV-101 evaluated in the study.
Other terminated trials from Aerovate Therapeutics
More terminations from Aerovate Therapeutics
Other Pulmonary Arterial Hypertension trials with similar outcome
Listed as NCT05036135, this PHASE2/PHASE3 trial focuses on Pulmonary Arterial Hypertension and remains terminated or withdrawn. Sponsored by Aerovate Therapeutics, it has been updated 22 times since 2021, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
22 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2/PHASE3
Status: Active Not Recruiting → Terminated
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2/PHASE3
Status: Recruiting → Active Not Recruiting · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2024 — Jun 2024 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 17 earlier versions
-
Feb 2024 — Apr 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2023 — Feb 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Aug 2023 — Oct 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE2_PHASE3
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2023 — May 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2022 — Feb 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2022 — Jun 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2022 — Apr 2022 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Oct 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Aerovate Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Albuquerque, United States , Almada, Portugal , Amsterdam, Netherlands , Ann Arbor, United States , Athens, Greece , Atlanta, United States , Aurora, United States , Barcelona, Spain , Beijing, China and 105 more locations